Abstract： Objective： To observe the clinical effect of Weifuchun Capsules as an adjuvant therapy of Oxaliplatin combined with Tegafur，Gimeracil and Oteracil Porassium in the treatment of advanced gastric cancer complicated with malignant ascites. Methods：A total of 86 cases of patients with advanced gastric cancer complicated with malignant ascites were selected and divided into the control group and the observation group according to the random number table method， with 41 and 45 cases in each group respectively. The control group was treated with Oxaliplatin combined with Tegafur，Gimeracil and Oteracil Porassium， and the observation group was additionally treated with Weifuchun Capsules based on the treatment of the control group. Both groups were continuously treated for 42 days. The RECIST short-term clinical effects and the incidence of adverse reactions were compared between the two groups. Traditional Chinese medicine (TCM) syndrome scores and the scores of Karnofsky Performance Status Scale (KPS) were compared between the two groups before and after treatment. Results：The total effective rate was 33.33% in the observation group， higher than that of 14.63% in the control group， there being no significance in the difference (P＞0.05). After treatment，KPS scores in the two groups were increased (P＜ 0.05)， and TCM syndrome scores were decreased (P＜0.05)； KPS score in the observation group was higher than that in the control group (P＜0.05)， and TCM syndrome score in the observation group was lower than that in the control group (P＜0.05). The incidence of diarrhea in the observation group was lower than that in the control group (P＜0.05). Conclusion：For patients with advanced gastric cancer complicated with malignant ascites，Weifuchun Capsules as an adjuvant therapy of Oxaliplatin combined with Tegafur， Gimeracil and Oteracil Porassium can relieve clinical symptoms， improve quality of life， and reduce the incidence of adverse reactions.